IN2015DN01738A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01738A IN2015DN01738A IN1738DEN2015A IN2015DN01738A IN 2015DN01738 A IN2015DN01738 A IN 2015DN01738A IN 1738DEN2015 A IN1738DEN2015 A IN 1738DEN2015A IN 2015DN01738 A IN2015DN01738 A IN 2015DN01738A
- Authority
- IN
- India
- Prior art keywords
- irbesartan
- coa reductase
- reductase inhibitor
- hmg coa
- independent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Abstract
Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and 2) an independent HMG CoA reductase inhibitor unit comprising an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and an alkaline additive wherein said independent units are separated from each other within a capsule and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG CoA reductase inhibitor the pharmaceutical composite capsule formulation is improved in stability and dissolution rate and thus shows great bioavailability. In addition the formulation is expected to guarantee high drug compliance owing to its small size and therefore can be applied to the treatment of hypertension and hypercholesterolemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120096036A KR20140030505A (en) | 2012-08-31 | 2012-08-31 | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor |
PCT/KR2013/007841 WO2014035190A1 (en) | 2012-08-31 | 2013-08-30 | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01738A true IN2015DN01738A (en) | 2015-05-29 |
Family
ID=50183919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1738DEN2015 IN2015DN01738A (en) | 2012-08-31 | 2013-08-30 |
Country Status (28)
Country | Link |
---|---|
US (1) | US20150231085A1 (en) |
EP (1) | EP2890371A4 (en) |
JP (1) | JP2015526509A (en) |
KR (1) | KR20140030505A (en) |
CN (1) | CN104602678A (en) |
AR (1) | AR092385A1 (en) |
AU (1) | AU2013309688A1 (en) |
BR (1) | BR112015004091A2 (en) |
CA (1) | CA2882738A1 (en) |
CL (1) | CL2015000363A1 (en) |
CO (1) | CO7350622A2 (en) |
CR (1) | CR20150124A (en) |
DO (1) | DOP2015000042A (en) |
EA (1) | EA201590474A1 (en) |
EC (1) | ECSP15010617A (en) |
IL (1) | IL237425A0 (en) |
IN (1) | IN2015DN01738A (en) |
MA (1) | MA37953A1 (en) |
MX (1) | MX2015002591A (en) |
NI (1) | NI201500028A (en) |
PE (1) | PE20150402A1 (en) |
PH (1) | PH12015500395A1 (en) |
RU (1) | RU2015111523A (en) |
SG (1) | SG11201500580QA (en) |
TW (1) | TW201414511A (en) |
UY (1) | UY35000A (en) |
WO (1) | WO2014035190A1 (en) |
ZA (1) | ZA201502157B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101771766B1 (en) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | Pharmaceutical combination comprising Angiotensin-Ⅱ Receptor Blocker and HMG-CoA Reductase Inhibitor |
EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
TWI805599B (en) * | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | Formulations of a compound modulating kinases |
CN110237070A (en) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | Irbesartan is preparing the application in blood lipid-lowering medicine |
CN113476423A (en) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | Preparation method of rosuvastatin calcium capsule and rosuvastatin calcium capsule |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI20109A (en) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stable pharmaceutical formulation |
PE20030324A1 (en) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN |
PL1750862T3 (en) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Pharmaceutical composition containing irbesartan |
WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
CN101980701A (en) * | 2008-03-28 | 2011-02-23 | 菲尔若国际公司 | Capsule for the prevention of cardiovascular diseases |
KR101205633B1 (en) * | 2008-04-29 | 2012-11-27 | 한올바이오파마주식회사 | Pharmaceutical formulation for treating cardiovascular disease |
AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
KR101248804B1 (en) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN |
US9056134B2 (en) * | 2010-07-21 | 2015-06-16 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/en active Search and Examination
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/en unknown
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/en active Application Filing
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/en not_active IP Right Cessation
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 CA CA2882738A patent/CA2882738A1/en not_active Abandoned
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/en active Pending
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/en not_active Application Discontinuation
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/en not_active Application Discontinuation
- 2013-08-30 TW TW102131242A patent/TW201414511A/en unknown
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/en not_active Withdrawn
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/en unknown
- 2013-08-30 UY UY0001035000A patent/UY35000A/en not_active Application Discontinuation
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/en active Pending
- 2013-08-30 EA EA201590474A patent/EA201590474A1/en unknown
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/en unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/en unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/en unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/en unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/en unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/en unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/en unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2882738A1 (en) | 2014-03-06 |
PH12015500395A1 (en) | 2015-04-27 |
CO7350622A2 (en) | 2015-08-10 |
KR20140030505A (en) | 2014-03-12 |
US20150231085A1 (en) | 2015-08-20 |
CL2015000363A1 (en) | 2015-06-05 |
UY35000A (en) | 2014-03-31 |
EP2890371A4 (en) | 2016-04-06 |
IL237425A0 (en) | 2015-04-30 |
PE20150402A1 (en) | 2015-04-13 |
WO2014035190A1 (en) | 2014-03-06 |
TW201414511A (en) | 2014-04-16 |
MA37953A1 (en) | 2017-01-31 |
CR20150124A (en) | 2015-04-24 |
AR092385A1 (en) | 2015-04-22 |
AU2013309688A1 (en) | 2015-02-26 |
DOP2015000042A (en) | 2015-04-30 |
RU2015111523A (en) | 2016-10-20 |
JP2015526509A (en) | 2015-09-10 |
SG11201500580QA (en) | 2015-02-27 |
EP2890371A1 (en) | 2015-07-08 |
EA201590474A1 (en) | 2015-06-30 |
ECSP15010617A (en) | 2015-12-31 |
BR112015004091A2 (en) | 2017-07-04 |
NI201500028A (en) | 2017-01-04 |
ZA201502157B (en) | 2016-10-26 |
CN104602678A (en) | 2015-05-06 |
MX2015002591A (en) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
MY157307A (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbersartan | |
PH12015500395A1 (en) | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor | |
RU2573392C3 (en) | COMPOSITION CONTAINING TETRACYCLIC COMPOUNDS | |
AU2012259422A8 (en) | Solid forms of a pharmaceutically active substance | |
RS53995B1 (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
WO2013112959A8 (en) | Antifibrotic compounds and uses thereof | |
IN2014MN02236A (en) | ||
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
UA112764C2 (en) | OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC CRYSTALLIC bile acids with a predetermined particle size | |
TR201001417A1 (en) | Cefdinir formulation with improved dissolution rate | |
EP3648745A4 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
MX359436B (en) | Pharmaceutical combined preparation containing hmg-coa reductase inhibitor and cholesterol absorption inhibitor. | |
IN2015DN02296A (en) | ||
MX370184B (en) | Pharmaceutical composition comprising fingolimod. | |
TN2012000568A1 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
PH12015500394A1 (en) | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate | |
EP2636677A4 (en) | Cdk-inhibiting pyrrolopyrimidinone carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating liver cell cancer | |
WO2013057569A3 (en) | Extended release pharmaceutical composition containing amoxicillin and clavulanic acid | |
IN2012CH03125A (en) | ||
WO2013054178A3 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
IN2014CN02343A (en) | Oral formulations containing hyaluronic acid for sustained drug release | |
TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
TR201005911A2 (en) | A drug formulation with improved dissolution profile. | |
NZ620698A (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods |